Lobbying Activity Report

1774-51437

Organization: Innovative Medicines Canada (Medicaments novateurs Canada)
Associated registration: 10310-1774-72
Lobbying Activity date: 2026-04-15
Arranged a meeting: Yes
Posted date: 2026-05-14

In-house lobbyists who participated in the lobbying activity: Charles Brown
Senior Public Office Holders who were lobbied in this activity: Bryan Tepper, MLA for Surrey-Panorama
Member(s) of the BC Legislative Assembly
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Advocate for the adoption of innovative payer agreements at the pan-Canadian level incorporating real world evidence.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Advocate regarding provincial government funding decisions for British Columbia’s PharmaCare program, including budget allocations.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Finances and Budgets, Health
Advocate regarding provincial policies governing the assessment, reimbursement and formulary listing of medicines in BC.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Engage with the BC government to improve access to innovative medicines and vaccines, and advance collaborative, data-driven procurement approaches that enhance patient outcomes, strengthen BC’s life sciences sector and promote health system sustainability.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Government Procurement, Health
Policy measures to ensure security of drug supply in BC and Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations and their impact on patient access and economic growth in British Columbia.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Economic Development and Trade, Health, Intellectual Property, International Relations, International Trade, Science and Technology
 
Senior officer who filed this Lobbying Activity Report: Bettina Hamelin
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.

Date Modified: